Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733676 | 0.79 | CYP19A1 (0.55) | CYP19A1SMN1; SMN2KDM4EMAPTALDH1A1 | |
| SCHEMBL933781 | 0.75 | KDM4E (0.51) | NPC1RAB9ASMN1; SMN2LMNAHTT | |
| SCHEMBL3703151 | 0.75 | RAB9A (0.49) | NPC1RAB9ASMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL25007407 | 0.75 | FFAR1 (0.55) | FFAR1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL1851646 | 0.73 | ADRA2A (0.41) | FFAR1NPC1RAB9ASMN1; SMN2DAO | |
| SCHEMBL3220494 | 0.73 | CYP19A1 (0.49) | CYP19A1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL7194163 | 0.72 | CYP19A1 (0.51) | CYP19A1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL31211720 | 0.72 | CYP19A1 (0.66) | CYP19A1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL933704 | 0.72 | MPO (0.41) | NPC1RAB9ASMN1; SMN2DAOKMT2A | |
| SCHEMBL3701792 | 0.71 | CYP19A1 (0.50) | CYP19A1NPC1RAB9ALMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173424-B2 | Pyridine derivatives with umami flavour | GIVAUDAN S.A. (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173424-B2 | Pyridine derivatives with umami flavour | GIVAUDAN S.A. (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173424-B2 | Pyridine derivatives with umami flavour | GIVAUDAN S.A. (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20140295045-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN S.A. (CH) | 2014-10-02 | — | — | US | disclosed |
| US-20140295045-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN S.A. (CH) | 2014-10-02 | — | — | US | disclosed |
| US-20140295045-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN S.A. (CH) | 2014-10-02 | — | — | US | disclosed |
| EP-2451781-B1 | PYRIDINE DERIVATIVES WITH UMAMI FLAVOUR | GIVAUDAN SA (CH) | 2013-09-18 | — | — | EP | disclosed |
| EP-2451781-B1 | PYRIDINE DERIVATIVES WITH UMAMI FLAVOUR | GIVAUDAN SA (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20120121783-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN SA (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120121783-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN SA (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120121783-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN SA (CH) | 2012-05-17 | — | — | US | disclosed |
| WO-2011004016-A1 | PYRIDINE DERIVATIVES WITH UMAMI FLAVOUR | GIVAUDAN SA (CH) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121783-A1 | Pyridine Derivatives With Umami Flavour | C5, CHRM1, C9 | CYP19A1 2965/4885FFAR1 452/4885NPC1 4083/4885 |
| US-20140295045-A1 | Pyridine Derivatives With Umami Flavour | C5, CHRM1, C9 | CYP19A1 3485/4885FFAR1 449/4885NPC1 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.